1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Pfizer’s Marstacimab Wins In Phase III, But Caution On Market Position, Clotting Remain

 
• By Alaric DeArment

The drug showed efficacy in hemophilia A and B with no sign of clots, an issue that historically has dogged anticoagulation agents, but it remains unclear whether that advantage will hold.

Pfizer announced Phase III results for marstacimab in hemophilia • Source: Shutterstock

Pfizer Inc. posted successful topline results from the Phase III BASIS study of marstacimab in hemophilia A and B, but it remains unclear how competitive it will be on the market once approved, particularly in hemophilia A, where Sanofi’s Altuviiio (efanesoctocog alfa) won US Food and Drug Administration approval just months ago and Roche Holding AG’s Hemlibra (emicizumab) has dominated since its approval in 2017.

While one analyst was cautiously optimistic about the lack of clotting events – historically an issue with drugs that target...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Allogene Sticks With Standard Lymphodepletion In CAR-T Trial After Patient Death

 
• By Alaric DeArment

The company said it will no longer use ALLO-647 after a patient developed a fatal adenovirus infection, and it will pursue further development of its Dagger technology to minimize or eliminate the need for lymphodepletion.

BioNTech Outlines Development Plan For PD-L1xVEGF-Targeting BNT-327

 
• By Jessica Merrill

The company, with partner Bristol Myers Squibb, has a three-wave development strategy for BNT-327: “establish, combine, broaden.”

AstraZeneca’s Tagrisso Mountain Grows, But The Climb Will Be Challenging

 
• By Aakash Babu

The UK major continues to post promising data readouts that further emphasize the safety and efficacy of its blockbuster lung cancer drug, but competition from J&J's Rybrevant is ramping up, and capable challengers are emerging.